WuXi AppTec Co., Ltd., a leading global pharmaceutical and medical device open-access capability and technology platform company, announced listing of its initial public offering (IPO) of 104,198,600 shares of common stock, at a public offering price of RMB 21.60 per share.

The aim to use the proceeds from the IPO to build and expand its R&D facilities in China, further strengthening its capabilities and capacities to better serve global customers and partners.

WuXi AppTec, headquartered in Shanghai, is now operating globally with 26 sites and branch offices in China, the United States, Germany, UK, Japan, Korea and Israel.  The Company's integrated R&D, manufacturing and testing platform for small molecules, cell and gene therapies, and medical devices is supporting over 3,000 customers and partners around the world.